Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Amgen hunts cancer with a modified herpes virus.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
In the following video, Motley Fool health-care analyst David Williamson discusses some very surprising trial results from Amgen (AMGN 0.01%). The company has announced phase 3 results that it has bioengineered a version of the herpes virus to attack melanoma, by singling out only fast-dividing cells. David tells us the possible ramifications both for investors and for patients.
Alert: Top Cash Back Card Now Offers 0% Intro APR Until Nearly 2027
Enjoy 0% intro APR on purchases and balance transfers for 15 months—plus up to 5% cash back in popular categories.